Low postoperative nonstimulated thyroglobulin as a criterion for the indication of low radioiodine activity in patients with papillary thyroid cancer of intermediate risk ‘with higher risk features’

2016 ◽  
Vol 85 (3) ◽  
pp. 453-458 ◽  
Author(s):  
Pedro Weslley Rosario ◽  
Gabriela Franco Mourão ◽  
Maria Regina Calsolari
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Alfredo Campennì ◽  
Rosaria M. Ruggeri ◽  
Giuseppe Giuffrè ◽  
Massimiliano Siracusa ◽  
Angela Alibrandi ◽  
...  

BMC Cancer ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Kevin Brennan ◽  
Christopher Holsinger ◽  
Chrysoula Dosiou ◽  
John B. Sunwoo ◽  
Haruko Akatsu ◽  
...  

2009 ◽  
Vol 94 (5) ◽  
pp. 1618-1622 ◽  
Author(s):  
Paolo Miccoli ◽  
Aldo Pinchera ◽  
Gabriele Materazzi ◽  
Agnese Biagini ◽  
Piero Berti ◽  
...  

Abstract Background: Minimally invasive video-assisted thyroidectomy (MIVAT) was introduced in the clinical practice to treat small benign thyroid nodules. This method has recently been demonstrated to produce the same completeness as a conventional thyroidectomy in patients with papillary thyroid cancer (PTC). The low number of treated cases and the limited follow-up of these patients represent the major limitations of these studies. Objective: The aim of the study was to compare the outcome of two groups of PTC patients, one treated with MIVAT and the other with conventional thyroidectomy, after a median follow-up of 5 yr. Study Group: A total of 221 PTC patients were enrolled in this study according to the following criteria: 171 were treated with MIVAT (group A), and 50 were treated with conventional thyroidectomy (group B). Results: The outcome and the cumulative 131I activity administered to achieve curative status were compared. After a mean follow-up of 3.6 ± 1.5 yr (range, 1–8 yr; median, 5 yr), no differences were found between group A and group B. A similar rate of permanent hypoparathyroidism and/or nerve cord palsy was found in both groups. Conclusion: We demonstrated that PTC patients operated on with MIVAT had a good outcome after 5 yr. This was similar to the outcome of patients treated with conventional thyroidectomy and the same degree of exposure to 131I. These results, together with the evidence of a similar degree of completeness and rate of complications between the two surgical techniques, show that MIVAT is a valid option to treat low- and intermediate-risk PTC patients.


2018 ◽  
Vol 2018 ◽  
pp. 1-3
Author(s):  
Anupama Roy Chowdhury ◽  
Jack Kian Ch’ng ◽  
Choon Chieh Tan

Papillary thyroid cancer (PTC) can present as a thyroid cyst. In its more aggressive form, PTC may be multifocal in nature and is associated with a poorer prognosis. In patients whom PTC is diagnosed incidentally after a diagnostic lobectomy, the decision whether to offer completion thyroidectomy is sometimes challenging to make if such patients fall in the ‘low-to-intermediate’ risk category. We present a case of a 55-year-old lady who had a predominantly cystic left thyroid nodule with no suspicious features on ultrasound as well as 2 subcentimetre simple right-sided cysts. She subsequently underwent left hemithyroidectomy, and this reported a T2 PTC in the thyroid cyst. This was followed by completion thyroidectomy which yielded the surprising finding of PTC in the two tiny right sided cysts. This case highlights the need for vigilance in managing patients with thyroid cysts even though thyroid ultrasound scan did not reveal any overt suspicious features.


2017 ◽  
Vol 8 (1) ◽  
pp. 23-27
Author(s):  
Rasha Hamdy Hamed

Abstract Aim This trial aimed to determine wether postoperative radioactive iodine(RAI) associated with a survival benefit among intermediate-risk Papillary Thyroid Cancer patients or not. Methods this study is a retrospective study of intermediate-risk papillary thyroid cancer patients that were treated with or without post operative RAI from 1st January 2002 till 1st January 2012. Overall survival (OS) and multivariate regression analyses were measured for all patients. Results 100 patients were included in this trial : 70 patients received postoperative RAI and 30 patients did not. The mean follow-up time was 7.1 (4.8 -15.1 years), and a median survival time could not be estimated. Overall survival at 10 years was 96% in the RAI vs 93% in the group without RAI (P < .001). RAI reduced risk of death by a 27% [hazard risk (HR) 0.73, confidence interval (CI) 0.64 - 0.84, P < .001]. Older patient age, male gende, larger tumor size, multifocal tumors, lymph node metastases, aggressive histology, vascular invasion, positive surgical margin, minimal extrathyroidal extension and absence of postoperative RAI were accompanied by compromised OS (all P ≤ .001). Conclusion This representative study addresses the survival advantage of RAI for with intermediate risk PTC patients but conducting of large prospective randomized controlled trial is still warranted.


Sign in / Sign up

Export Citation Format

Share Document